טוען...

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

PURPOSE: Activating FGFR2 mutations have been identified in ~10% of endometrioid endometrial cancers (ECs). We have previously reported that mutations in FGFR2 are associated with shorter disease free survival (DFS) in stage I/II EC patients. Here we sought to validate the prognostic importance of F...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Gynecol Oncol
Main Authors: Jeske, Yvette W., Ali, Shamshad, Byron, Sara A, Gao, Feng, Mannel, Robert S, Ghebre, Rahel G, DiSilvestro, Paul A, Lele, Shashikant B, Pearl, Michael L, Schmidt, Amy P, Lankes, Heather A, Ramirez, Nilsa C, Rasty, Golnar, Powell, Matthew, Goodfellow, Paul J, Pollock, Pamela M
פורמט: Artigo
שפה:Inglês
יצא לאור: 2017
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5433848/
https://ncbi.nlm.nih.gov/pubmed/28314589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2017.02.031
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!